Helsinn Healthcare SA
Via Pian Scairolo
About Helsinn Healthcare SAHelsinn is a privately owned cancer care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.
Please click here for Helsinn job opportunities.
Tweets by Helsinn
38 articles with Helsinn Healthcare SA
This week, the U.S. Supreme Court rejected Swiss pharmaceutical company Helsinn Healthcare S.A.’s claim that Teva Pharmaceutical violated patent rights when the Israel-based company released a generic version of its anti-nausea medicine, Aloxi.
Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma, a rare type of skin cancer.
Helsinn Group and MEI Pharma Announce That Pracinostat Has Received Orphan Drug Designation From the EMA for the Treatment of AML
The orphan drug designation is based on the scarcity of treatments for patients suffering from AMLand on positive Phase 2 study results.
Helsinn Announces Upcoming Presentation Of Phase III Data Of Nepa (Fosnetupitant/ Palonosetron) Iv At ESMO 2017
Helsinn And MEI Pharma Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
Helsinn Group Announces Upcoming Presentation Of Phase III Data In NEPA (Netupitant/Palonestron) At MASCC/ISOO Congress In Washington DC
Helsinn And MEI Pharma Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome
Helsinn And MEI Pharma Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
Mundipharma AG And Helsinn Expand Exclusive Licensing And Distribution Agreements For Leading Anti-emetic Products In Middle East, Africa, Latin America And Indonesia
Helsinn And MEI Pharma Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
Helsinn And MEI Pharma Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting
Helsinn Healthcare SA,The University of Texas MD Anderson Cancer Center Enter Strategic Alliance To Improve Life Of Patients Conducting Clinical Studies In Cancer Supportive And Palliative Care
Zealand Pharma And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea